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The venom of the Australian lowlands copperhead, Austrelaps superbus, produces 
significant and potentially lethal neurotoxic paralysis in cases of clinical envenomation. 
However, little is known about the neurotoxic components within this venom or venoms 
from the related alpine copperhead (Austrelaps ramsayi) or pygmy copperhead 
(Austrelaps labialis). Using the isolated chick biventer cervicis nerve-muscle preparation, 
all Austrelaps venoms were found to exhibit potent and rapid inhibition of nerve-evoked 
twitch contractions and block of contractures to nicotinic agonists, consistent with 
postsynaptic neurotoxic activity. Following separation by size-exclusion liquid 
chromatography under non-denaturing conditions, all Austrelaps venoms were found to 
also contain a high molecular mass fraction with only weak phospholipase A2 (PLA2) 
activity that caused a slow inhibition of twitch contractions, without inhibiting contractures 
to nicotinic agonists. These actions are consistent with the presence of additional snake 
presynaptic PLA2 neurotoxin (SPAN) complexes in all three Austrelaps venoms. However, 
there was no evidence of direct muscle damage produced by any Austrelaps venom or 
SPAN complex. Monovalent tiger snake antivenom was effective in neutralising the 
neurotoxicity of both whole venom and the SPAN complex. However antivenom was 
unable to effectively reverse whole venom neurotoxicity, or prejunctional SPAN 
neurotoxicity, once established. Given the strong neurotoxicity of all Austrelaps venoms, 
particularly A. ramsayi and A. labialis, effective bites from these copperhead species 
should be considered potentially lethal. Furthermore, clinicians need to be aware of 
possible irreversible presynaptic neurotoxicity following envenomation from all copperhead 
species and that early antivenom intervention is important in preventing further 
development of toxicity.  
 
 




Despite Australia being home to some of the world’s most venomous snakes, there are 
only around 2 deaths per year, despite 1000-3000 cases of snakebite (White, 1998). This 
is due to Australia possessing high quality species-specific antivenoms, well-trained 
emergency and intensive care medical services and effective first aid techniques that 
specifically assist in elapid snakebite (Currie, 2006). To maintain such a low rate of 
mortality, despite increasing population spread, adequate knowledge of the likely clinical 
actions of all potentially dangerous snake venoms is critical. 
An important complication of systemic envenomation by many Australian elapid snakes is 
skeletal muscle paralysis due to the presence of neurotoxins. If left untreated, systemic 
neurotoxicity can lead to paralysis of respiratory muscles, ultimately resulting in death by 
asphyxiation. Although these neurotoxic components have been pharmacologically 
characterised from the venoms of several Australian snakes, many others have been 
understudied. Members of the genus Austrelaps, the Australian copperheads (Worrell, 
1963; Serpentes: Elapidae: Acanthophiinae), are among those that have been poorly 
characterised with limited biochemical or pharmacological studies. Importantly these 
snakes should not be confused with North American copperheads belonging to the genus 
Agkistrodon. It is generally accepted that there are three species within the Austrelaps 
genus (Rawlinson, 1991): A. superbus (common or lowland copperhead, Günther, 1858), 
A. ramsayi (alpine or highland copperhead, Krefft, 1864) and A. labialis (pygmy or 
Adelaide Hills copperhead, Jan, 1859). These snakes prefer cooler climates and are 
usually found in damp areas around streams, rivers, swamps or marshlands and are 
distributed in the southeastern states of Victoria and Tasmania, the highlands of New 
South Wales and southern parts of South Australia (Fig. 1).  
Whilst there is a paucity of clinical data on copperhead envenoming, the toxicity of A. 
superbus venom has been established, with a median lethal dose (LD50) of 0.50 mg/kg 
(s.c. in mice with 0.1% BSA), exactly the same lethality as that of the Indian cobra Naja 
naja (Broad et al., 1979). Furthermore, A. superbus has been attributed to at least one 
human fatality and profound paralysis in a dog following envenoming (Sutherland and 
Tibballs, 2001). Given the high venom potency and venom yield of 26-85 mg (Sutherland 
and Tibballs, 2001), A. superbus should be regarded as dangerous and capable of lethal 
envenomation. To date, a number of coagulopathic proteins, including anticoagulants and 
inhibitors of platelet aggregation have been characterised from this venom (Singh et al., 
2000; Subburaju and Kini, 1997; Yuan et al., 1993) and one study has reported the 
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presence of myotoxic fractions causing myoglobinuria (Mebs and Samejima, 1980). 
However, while an anticoagulation coagulopathy is observed, symptoms of major myolysis 
and defibrination coagulopathy are not commonly observed in a clinical setting as they are 
with tiger snake envenoming. Despite these studies, there is very limited knowledge about 
the neurotoxicity of this venom with a single study indicating the likely presence of 
postsynaptic neurotoxins (Hodgson et al., 2003). 
While the yield of venom from A. ramsayi and A. labialis is very low, the LD50 values were 
found to be 0.6 mg/kg and 1.3 mg/kg, respectively (Sutherland and Tibballs, 2001). 
However there is little data available about the venom components of these two species 
compared to A. superbus. To date, there is only one study that describes the venom 
composition of A. ramsayi using a proteomics approach to identify proteins by mass and 
sequence homology (Birrell et al., 2007). Similarly, there is a single published study 
describing the venom composition of A. labialis, using transcriptomics to sequence cDNA 
from the venom gland of a specimen and identify proteins by sequence homology (Doley 
et al., 2008). A limitation with proteomics- and transcriptomics-based approaches is that 
proteins identified by sequence homology provide little if any information about their 
pharmacological action(s) or their potency, nor can they identify non-covalently bound 
protein complexes. These previous studies have shown that secretory phospholipase A2 
(sPLA2) enzymes are present in the venoms of all three copperheads (Birrell et al., 2007; 
Doley et al., 2008). However, the pharmacological activities of sPLA2 enzymes are quite 
diverse: neurotoxic ± myotoxic, cardiotoxic, convulsant or coagulopathic activity (Kini, 
1997).  
In addition to the common postsynaptic α-neurotoxins that block junctional nicotinic 
acetylcholine (ACh) receptors, monomeric SPANs (Harris et al., 1973) and multimeric 
SPAN complexes (Blacklow et al., 2010a; Chaisakul et al., 2010; Fohlman et al., 1976; 
Hodgson et al., 2007; Su et al., 1983) have been isolated from the venom of several 
Australo-Papuan elapid snakes. SPANs bind irreversibly to the presynaptic nerve terminal 
at the skeletal neuromuscular junction to inhibit the release of ACh without affecting the 
sensitivity of the motor endplate to ACh. Given that these toxins block neurotransmitter 
release in a potent and irreversible fashion, in addition to damaging the nerve terminal, 
knowledge of their presence can have implications for the management of envenomed 
patients. Therefore, in vitro studies are critical to determine the pharmacological actions of 
the components within these venoms, with particular attention paid to neurotoxic 
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components that are responsible for the most serious complications in systemic 
copperhead envenomation. 
Despite a series of monovalent antivenoms being available to treat envenomation by a 
range of different Australo-Papuan snakes, there are no specific antivenoms to treat 
several potentially lethal snakes, including copperheads. In these cases, monovalent 
antivenoms raised against other species are used, although recent evidence would 
suggest that Australian snake antivenoms are polyvalent and contain varying amounts of 
all five terrestrial snake monovalent antibodies (O'Leary and Isbister, 2009). Australian 
copperheads appear to share considerable biochemical, anatomical and ecological 
similarities with tiger snakes from the genus Notechis (Harris et al., 2000). Therefore it is 
not surprising that the accepted treatment for envenomation by copperheads is the 
administration of monovalent tiger snake antivenom (TSAV) (White, 2001). However, there 
is only one in vitro study (Hodgson et al., 2003) and one clinical report (Sutherland and 
Tibballs, 2001) demonstrating the efficacy of TSAV in preventing and reversing 
neurotoxicity associated with A. superbus venom. Furthermore, no studies have 
investigated the efficacy or effectiveness of TSAV to neutralise the toxicity of A. ramsayi 
and A. labialis venoms or prevent envenoming in human cases. Therefore knowledge of 
the in vitro efficacy of antivenom in preventing or reversing toxicity is critical to establish 
antivenom efficacy and provide supporting evidence to validate antivenom 
recommendations in clinical cases. 
This study aimed to identify the presence of any post- or presynaptic neurotoxicity in the 
venoms of three Austrelaps spp., particularly the presence of any high molecular mass 
multimeric SPAN complexes. The study also aimed to determine the in vitro efficacy of 
monovalent TSAV in preventing or reversing the neurotoxicity of whole venoms or 
presynaptic neurotoxicity associated with any multimeric SPAN complexes. 
 
2. Materials and Methods 
2.1 Venom source and storage 
Pooled A. superbus and pooled A. labialis venom was purchased from Venom Supplies 
Pty Ltd (Tanunda, SA). Copperheads were collected from their natural habitats in the Mt. 
Gambier and Kangaroo Island areas, respectively (Fig. 1). To minimise the effects of 
individual variations in venom (Chippaux et al., 1991), venom was collected from several 
snakes, pooled and lyophilized by the supplier. Due to limited availability of specimens, A. 
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ramsayi venom milked from an individual snake was purchased from the Melbourne 
Museum (Melbourne, VIC), originally sourced from the Davies Plain region of Victoria. 
Venoms were collected from fang tips by the specimen biting down on a parafilm covered 
bottle and injecting the venom into a polyethylene container, in combination with the use of 
a polyethylene pipette tip to milk any residual venom from the fang. All venoms were 
supplied lyophilised and were stored at –20°C. 
2.2 Size-exclusion FPLC under non-reducing conditions 
Bioassay-guided fractionation of venom was performed using a Shimadzu LC-10 HPLC 
system. Lyophilised venoms were dissolved in ammonium acetate buffer (0.1 M, pH 6.8) 
and insoluble material was removed by centrifugation at 10,000 rpm for 5 min (MiniSpin 
Plus centrifuge; Eppendorf, North Ryde, NSW, Australia). The supernatants (equivalent to 
ca. 3 mg of venom) were then applied to a Superdex G-75 fast-perfusion liquid 
chromatography (FPLC) column (10 × 300 mm, 13 µm; GE Healthcare, Sydney, NSW, 
Australia). The column was equilibrated with ammonium acetate buffer and samples were 
eluted isocratically at a flow rate of 0.75 ml/min. Eluting peaks were monitored at an 
absorbance of 214 and 280 nm and were collected manually prior to freeze-drying for 
subsequent toxicity testing. An estimation of the molecular mass of major fractions was 
made by calibrating the size-exclusion column with a series of protein standards (6.5–66 
kDa) using the molecular weight marker kit for gel filtration chromatography (MWGF-70; 
Sigma-Aldrich, St. Louis, MO) at a flow rate of 0.75 ml/min. The void volume (Vo) of the 
column was determined by running blue dextran (2000 kDa), and the elution volumes (Ve) 
for each molecular weight standard was calculated. The estimated molecular mass of the 
venom fractions was determined by interpolation of a plot of log molecular mass (Da) 
versus retention ratio (Ve/ Vo) of the standards. 
2.3 Bicinchoninic acid protein assay 
Following lyophilisation of fractionated venom components, protein concentration was 
determined using the Quantipro™ bicinchoninic acid (BCA) protein assay kit (Sigma-
Aldrich). Protein concentrations from 0.5-30 µg/ml were measured at 560 nm using a 
Titertek Multiscan® PLUS MKII (type 313) plate reader (Flow laboratories Australasia, 
North Ryde, NSW, Australia). Protein concentration was interpolated from a standard 
curve of various concentrations of bovine serum albumin type XI (Sigma-Aldrich). Yields 
were then expressed as a percentage of whole venom loaded onto the size-exclusion 
column (3 mg). 
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2.4 Isolated chick biventer cervicis nerve-muscle preparation 
Whole venom and individual fractions were tested in vitro for neurotoxic and myotoxic 
activity using the indirectly-stimulated isolated chick biventer cervicis nerve-muscle 
(CBCNM) preparation (Ginsborg and Warriner, 1960). Male Australorp chicks aged 1-8 
days-old were euthanased with CO2 and exsanguinated in accordance with Institutional 
Animal Care & Ethics Committee approval conforming to the Australian NHMRC Code of 
Practice for the use of animals in research. Each biventer cervicis muscle with 
accompanying nerve was attached to an isometric force transducer (ADInstruments, Belle 
Vista, NSW, Australia) and mounted in an 8 ml jacketed organ bath under 1 gram of 
resting tension. Organ baths contained Krebs-Henseleit solution of the following 
composition (mM): NaCl, 118.4; KCl, 4.7; MgSO4, 1.2; KH2PO4, 1.2; NaHCO3, 25.0; D-
glucose, 11.1; and CaCl2, 2.5. This solution was bubbled with carbogen (95% O2, 5% CO2) 
and was maintained at a temperature of 34oC using a Thermomix®M water pump and 
heating system (Braun, Melsungen, Germany). Silver ring electrodes were placed around 
the motor nerve to provide indirect stimulation using supramaximal 30 volt square-wave 
pulses of 0.2 ms duration at 0.1 Hz via a Grass S88 stimulator (Grass Medical 
Instruments, Quincy, Massachusetts, USA). Data was recorded digitally using a Powerlab 
2/25 data acquisition system and MACCHART v6.1.1 software (ADInstruments). The nerve-
muscle preparation was left to equilibrate for at least 30 minutes prior to experimentation. 
Exclusive electrical stimulation of the nerve was confirmed by complete blockade of 
twitches using 10 µM d-tubocurarine. Contracture responses to exogenous agonists 
before, and after, the addition of venom or individual fractions were recorded in the 
absence of indirect stimulation. The final bath concentrations and incubation times for the 
agonists were: ACh (1 mM, 30 s); carbachol (CCh; 20 µM, 60 s) and KCl (40 mM, 30 s) 
(Harvey et al., 1994). Washout was then repeated until twitch tension returned to its 
original amplitude. In all experiments, venom or individual venom fraction (10 µg/ml) was 
left in contact with the preparation until twitch contractions were abolished, or for a 
maximum of 3 hours if complete block of twitch contractions did not eventuate. Time-
matched controls confirmed that muscle fatigue was not significant at 3 hours after 
introduction of muscles into the organ bath. Muscle tension from isometric force 
transducers was amplified using a ML221 bridge amplifier (ADInstruments) and recorded 
using a Powerlab 2/25 system (ADInstruments) connected to an iMac or PC computer. 
Data were digitised at 140 Hz and filtered using 50 Hz high-pass and 20–200 Hz low-pass 
filters. 
F. Marcon and G. M. Nicholson Neurotoxicity of Australian copperhead snake venoms 
 
 8 
2.5 Antivenom reversibility studies 
The efficacy of TSAV (CSL Biotherapies, Melbourne, Australia) to neutralize the activity of 
venom or venom fractions was assessed by preincubating the organ bath with 5 U/ml 
TSAV for 10 min prior to addition of toxin. To better approximate a clinical situation, 
reversibility studies were also performed by the addition of 5 U/ml monovalent TSAV at 
90% inhibition of twitch contractions (t90).  
2.6 Secretory phospholipase A2 assay 
Determination of the PLA2 activity of whole venom (1 µg/ml) and separated venom 
components (1 µg/ml) was determined using a colourimetric sPLA2 assay kit (Cayman 
Chemical Ltd., Ann Arbor, MI, USA). This assay uses a 1,2-dithio analogue of diheptanoyl 
phosphatidylcholine as a substrate. Upon hydrolysis of the thio ester bond at the sn-2 
position by a PLA2 enzyme, free thiols are detected using 5,5’-dithio-bis-2-nitrobenzoic 
acid, producing a yellow colour. Absorbance was measured at 405 nm using the program 
KINETIC COLLECTOR v2 and a BIO-RAD model 3550-UV plate reader. Sample mix time was 
2 seconds with sampling every 20 seconds for 5 min. PLA2 activity was expressed as 
micromoles of phosphatidylcholine hydrolysed per minute per milligram (µmol/min/mg) of 
enzyme. Whole bee venom (Apis mellifera) (1 µg/ml) was used as a positive control. 
2.7 Mass spectrometry 
Matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) mass spectrometry 
was performed on a Voyager DE STR mass spectrometer with a nitrogen laser (337 nm; 2 
ns pulse) from PE Biosystems (Framingham, MA, USA). All analyses were performed in 
the positive ion linear mode with delayed extraction. Crude venom samples were dissolved 
in MilliQ water (1 mg/ml). Samples (0.1-0.2 µL) were mixed on plate containing 0.8-1.0 µL 
caffeic acid matrix [10 mg/ml in trifluoroacetic acid-water-acetonitrile (0.1:20:80, v/v/v)]. 
Spectra were calibrated with a mixture of synthetic standards (Calmix 3, 5.7-17 kDa mass 
range) in the Sequazyme® peptide mass standards kit (Applied Biosystems, Melbourne, 
Australia) using the same matrix. Spectra were processed using DATA EXPLORER software 
(Applied Biosystems). 
2.8 Chemicals and drugs 
Unless otherwise specified, all chemicals used were of analytical grade and supplied by 
Sigma-Aldrich, Castle Hill, NSW, Australia. 
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2.9 Data analysis 
Twitch tension and contractile responses to exogenous agonists were expressed as a 
percentage of the corresponding value before the addition of venom or purified venom 
fractions. The time taken to reduce the indirectly-stimulated twitch contractions by 90% 
(t90) was calculated to provide a quantitative measure of neurotoxicity. Values for t90 were 
calculated for each experiment by determining the elapsed time after toxin addition at 10% 
of the initial twitch contraction amplitude, and then the means and standard error of the 
means (SEM) were calculated. Statistical differences were determined by a one-way or 
two-way analysis of variance (ANOVA). All ANOVAs were followed by pairwise multiple 
comparisons using a Bonferroni post-hoc test, and a p-value of 0.05 was employed for all 
statistical analyses. Statistical and linear regression analyses were accomplished using 
PRISM 5.0 software package (GraphPad Software, San Diego, CA, USA). Unless otherwise 
stated, data are expressed as the mean ± SEM. 
 
3. Results 
3.1 Neurotoxicity of whole venom 
All Austrelaps venoms (10 µg/ml) produced a rapid block of indirectly-stimulated (nerve-
evoked) twitch contractions in the isolated CBCNM preparation as compared to time-
matched controls (Fig. 2Aa and closed circles in Fig. 2C-E). The times to 90% 
neuromuscular blockade (t90) for inhibition of twitch tension by A. superbus, A. ramsayi and 
A. labialis were 48 ± 5 min (n = 12), 20 ± 1 min (n = 3) and 24 ± 1 min (n = 5), respectively 
(Fig. 2F). The t90 values of A. ramsayi and A. labialis venoms were not significantly 
different (p > 0.05, one-way ANOVA), however both venoms produced significantly more 
rapid neuromuscular blockade than A. superbus venom (p < 0.05 in both cases, one-way 
ANOVA; Fig. 2F). All venoms also caused significant inhibition of contractile responses to 
the exogenous nicotinic agonists, ACh and CCh (p < 0.001–0.0001, two-way ANOVA; Fig. 
3A and black bars in Fig. 3B-C). This is indicative of postsynaptic neurotoxicity with all 
three Austrelaps venoms. However, there was no significant inhibition of contractile 
responses to KCl (p > 0.05, two-way ANOVA; black bars in Fig. 3D), and no change in 
baseline muscle tension (eg. Fig. 2A), indicating a lack of overt myotoxicity with any of 
these venoms.  
Monovalent tiger snake antivenom (5 U/ml), added to the isolated CBCNM preparation 10 
min prior to the addition of venom, was able to effectively neutralise the neurotoxic 
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components of all three venoms. Antivenom prevented any significant inhibition of twitch 
contractions (p > 0.05 vs. time-matched control, one-way ANOVA; Fig 2B and grey circles 
in Fig. 2C-E) or nicotinic agonist responses (p > 0.05, two-way ANOVA; grey bars in Fig. 
3B-C) by all three venoms.  
Due to the presence of rapidly-acting postsynaptic neurotoxicity, the presence of any 
slower-acting presynaptic neurotoxins within these venoms is likely to be masked. To 
ascertain if Austrelaps venoms contain irreversible presynaptic neurotoxic component(s), 5 
U/ml TSAV was added to the isolated CBCNM preparation at 90% neuromuscular 
blockade (t90). The potential presence of presynaptic neurotoxins would be indicated by a 
lack of reversal of twitch tension but the return of exogenous nicotinic agonist responses. 
After a 3 hour TSAV application period, there was no restoration of twitch contractions with 
either A. superbus or A. labialis venoms and neuromuscular transmission remained 
completely inhibited (p < 0.0001 vs. time-matched control for both venoms, one-way 
ANOVA; open circles in Figs. 2B and 2D). In contrast, there was a partial recovery of 
twitch contractions when TSAV was added at t90 following application of A. ramsayi venom 
(Fig. 2Ab) but this was still inhibited compared to time-matched controls (35 ± 1%, n = 2 
due to limited material, open circles in Fig. 2C). Importantly, however, contractile 
responses to ACh were restored to control levels following application of TSAV at t90 with 
all three venoms (p > 0.05 vs. control, two-way ANOVA; open bars in Fig. 3B). Overall, 
these results are consistent with the likely presence of an irreversible presynaptic 
component within each Austrelaps venom. The partial recovery of A. ramsayi venom-
induced neuromuscular blockade following TSAV may also indicate the presence of less 
potent or lower abundance presynaptic neurotoxins. Interestingly, contractile responses to 
CCh were not significantly reversed following application of 5 U/ml TSAV at the t90 value 
for all three venoms (open bars in Fig. 3C). This reversal of ACh responses, but not CCh 
responses, following application of antivenom has been previously noted for pseudo-
irreversible postsynaptic α-neurotoxins such as papuantoxin-1 (Kuruppu et al., 2005b).  
3.2 Venom fractionation  
Fractionation of Austrelaps spp. venoms using size-exclusion FPLC, under non-reducing 
conditions, produced 4-6 major peaks with a similar chromatographic pattern (Fig. 4B-D). 
Following calibration of the size-exclusion column using a set of molecular mass markers 
(Fig. 4A), the retention times of early-eluting fractions were found to be consistent with a 
molecular mass range between 41 kDa to >66 kDa (early shaded fraction labelled ‘ƒ1’ in 
Fig. 4B-D). Given that the calibration of the size-exclusion Sephadex G-75 column may not 
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be linear beyond 66 kDa (bovine serum albumin was the highest mass calibrant tested) or 
below 6.5 kDa (aprotinin was the lowest mass calibrant tested), we have elected not to 
extrapolate beyond these upper and lower limits. Considering that the smallest known 
multimeric SPAN complex is dimeric β-bungarotoxin (21 kDa) (Chu et al., 1995) and the 
largest is hexameric textilotoxin (ca. 87 kDa) (Aquilina, 2009), the criteria used to 
determine the presence of a SPAN complex in the present study was therefore that the 
molecular mass range of the first eluting fraction had to fall between these two masses. 
The retention ratio (Ve / Vo) and molecular mass range of the early eluting fraction (ƒ1) 
were consistent with the presence of a large molecular mass component within this 
fraction in all three Austrelaps venoms (Table 1). The percent yield of each high molecular 
mass ƒ1 fraction, as determined by the BCA protein assay, varied between 4.9–14.4% 
(Table 1). In the lower mass regions of the venom profile, each venom presented distinct 
differences in the abundance of proteins with retention times consistent with monomeric 
sPLA2 proteins (17–17.4 min, 12,700–14,800 kDa) or postsynaptic α-neurotoxins (18.4–
19.2 min, 6,700–8,850 kDa). Austrelaps superbus venom was significantly richer in 
monomeric sPLA2 proteins, A. ramsayi was almost completely dominated by postsynaptic 
α-neurotoxins, while A. labialis appears to express both types of proteins to a similar 
degree.  
3.3 Neurotoxicity studies of the high molecular mass fraction 
To determine the presence of any multimeric SPAN complex, each high molecular mass 
ƒ1 fraction (10 µg/ml) was bioassayed using the isolated CBCNM preparation. The ƒ1 
fraction from all three venoms produced a slow time-dependent inhibition of indirect twitch 
contractions (closed squares in Fig. 5A-C) whereas with time-matched controls there was 
no significant inhibition of twitch tension over a 270 min period (open triangles in Fig. 5A-
C). The t90 values for inhibition of twitch tension by A. superbus, A. ramsayi and A. labialis 
were 130 ± 2 min (n = 6), 69 ± 3 min (n = 3) and 68 ± 6 min (n = 3), respectively (Fig. 5D). 
The t90 values for fraction ƒ1 from A. ramsayi and A. labialis venoms were not significantly 
different (p > 0.05, one-way ANOVA), however both ƒ1 fractions produced significantly 
more rapid neuromuscular blockade than fraction ƒ1 from A. superbus venom (p < 0.0001 
in both cases, one-way ANOVA; Fig. 5E). Despite a potent, albeit slow, action to 
completely inhibit twitch contractions, fraction ƒ1 from all Austrelaps venoms failed to 
significantly inhibit contractile responses to ACh, CCh or KCl, and there was no change in 
baseline muscle tension (p > 0.05, two-way ANOVA; Fig. 6A-C). This is indicative of 
presynaptic neurotoxicity without overt direct muscle damage within fraction ƒ1 from all 
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three Austrelaps venoms. These actions are consistent with the presence of an irreversible 
multimeric SPAN complex.  
Addition of 5 U/ml TSAV to the isolated CBCNM preparation 10 min prior to the addition of 
fraction ƒ1, was able to effectively neutralise the neurotoxic activity of fraction ƒ1 from A. 
superbus and A. labialis venoms (fraction ƒ1 from A. ramsayi was not tested due to limited 
material) (p > 0.05 vs. time-matched control, one-way ANOVA; grey squares in Figs. 5B 
and 5D). Contractile responses to ACh, CCh and KCl remained uninhibited (p > 0.05 vs. 
control, two-way ANOVA; open bars in Figs. 6A-C). 
Addition of 5 U/ml TSAV at 90% neuromuscular blockade (i.e. at t90), induced by each 
fraction ƒ1, failed to restore neuromuscular transmission. After a 130-230 min TSAV 
application period, there was no restoration of twitch contractions with fraction ƒ1 from any 
Austrelaps venom and neuromuscular transmission remained completely inhibited (p < 
0.0001 vs. time-matched control for all venoms, one-way ANOVA; open squares in Figs. 
5A-C).  
Contractile responses to ACh, CCh and KCl also remained uninhibited in the presence of 
ƒ1 (p > 0.05 vs. time-matched control, two-way ANOVA; closed bars in Fig. 6A-C). 
Interestingly, the responses to CCh and, to a lesser extent, ACh were significantly 
enhanced in toxin-free time-matched controls recorded at 3-5 hours in comparison to 
responses recorded at time zero (striped bars vs. dashed line in Fig. 6A-C). This may 
reflect time-dependent sensitization of the tissue to cholinergic agonists in the absence of 
nicotinic receptor antagonists, and has been previously reported in the CBCNM 
preparation (Blacklow et al., 2010a; Kuruppu et al., 2005a; Lumsden et al., 2005). 
3.4 PLA2 activity 
The PLA2 activity of the positive control, bee venom, was 262 ± 14 µmol/min/mg (n = 11), 
comparable to previous studies. However, the PLA2 activity of whole Austrelaps venoms 
and ƒ1 fractions were significantly lower than the positive control. In addition, the PLA2 
activity of whole venoms and ƒ1 neurotoxic fractions from Austrelaps spp. showed 
considerable within-genus variability (Fig. 7). PLA2 activity of the least neurotoxic venom 
from A. superbus possessed the highest enzymatic activity of 152 ± 5 (whole venom, n = 
3) and 7 ± 2 (ƒ1 fraction, n = 4) µmol/min/mg. In contrast, the PLA2 activity of both whole 
venom and ƒ1 fraction from A. ramsayi, which both caused marked neurotoxicity, could not 
be detected in the same assay. In support, phospholipase A2 activity of less than 1 
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µmol/min/mg has been previously reported for some Australian elapid venoms including 
several Pseudechis spp., as well as Notechis scutatus (Ramasamy et al., 2004). 
 
3.5 Mass spectrometry 
All venoms shared a similar pattern of components in their size-exclusion FPLC 
chromatograms. However, there were differences in the retention time and relative 
absorbance of these components between Austrelaps venoms. To determine any similarity 
between these venoms, in terms of the types of toxins they contain and their relative 
abundance, a mass profile of each venom was obtained using MALDI-TOF mass 
spectrometry. The mass spectra were dominated by high-intensity ions in the m/z regions 
of 6300–6700, 6700–6900, 7300–8300 and 12700–14800 m/z ranges (Fig. 8). These 
mass ranges are consistent with Kunitz-type protease inhibitors, short-chain α-neurotoxins, 
long-chain α-neurotoxins and sPLA2 proteins, respectively. Unfortunately, this data does 
not indicate if any sPLA2 proteins are monomeric SPANs, coagulopathic or myotoxic 
sPLA2 proteins, or represent dissociated sPLA2 components of a multimeric SPAN 
complex. Allowing for minor differences in measurement from external calibration, all 
venoms share comparable short-chain α-neurotoxins at m/z 6767, also previously reported 
using LC-ESI mass spectrometry (Hodgson et al., 2003), and A. superbus and A. labialis 
share comparable short-chain α-neurotoxins at m/z 6817 (see highlighted masses in Fig. 
8), although the molecular identity of these proteins would need to be confirmed via 
Edman sequencing. A. superbus and A. labialis also share comparable long-chain α-
neurotoxins at m/z 7336 and 7352 and sPLA2 proteins at m/z 13529, while A. ramsayi and 
A. labialis share comparable long-chain α-neurotoxins at m/z 8071. Interestingly, A. 
ramsayi has a low abundance of sPLA2 proteins and does not share any equivalent sPLA2 
proteins with A. superbus or A. labialis. A. ramsayi venom is also dominated mainly by the 
presence of long-chain α-neurotoxins. This finding is also supported by the size-exclusion 
FPLC chromatogram profile (Fig. 4C). These differences may result from different prey 
species and resultant selection pressures on venom composition given that the A. ramsayi 
is restricted to higher altitudes and more northerly areas. Indeed, it is the only Australian 
venomous snake that lives above the snowline.  
Perhaps the majority of sPLA2 proteins detected in the MALDI-TOF mass spectra for A. 
ramsayi venom are only associated with the multimeric SPAN complex and do not exist as 
monomers. This would explain why the relative absorbance of the ‘PLA2' fractions in the 
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size-exclusion chromatogram for A. ramsayi was so much lower than that of A. superbus 
and A. labialis. 
 
4. Discussion 
The venoms of all three species of Australian copperhead were found to contain clear 
evidence of postsynaptic neurotoxicity, as demonstrated by the rapid inhibition of nerve-
mediated twitch contractions and the inhibition of contractile responses to exogenous 
nicotinic receptor agonists. Furthermore, these results are supported by the presence of a 
range of short- and/or long-chain postsynaptic α-neurotoxins in the MALDI-TOF analysis of 
all Austrelaps venoms.  
Vertebrate LD50 studies, as a means to rank snake venom lethality, have been largely 
superseded by in vitro studies as a result of the complex regulatory requirements and 
ethical considerations in Australia and many other countries. To overcome this issue, a 
common method of assessing snake venom neurotoxicity is to determine t90 values in 
isolated nerve-muscle preparations (Harvey et al., 1994). Austrelaps venoms display 
intermediary neurotoxic potency compared with other Australian elapid snakes, showing 
higher potency than taipan (Oxyuranus) and most black and mulga snake (Pseudechis) 
venoms, but less potency than death adder (Acanthophis) venoms (Table 2) and Indo-
Pacific sea snake venoms (Chetty et al., 2004). Of the three venoms, A. superbus venom 
displayed the least neurotoxicity (t90 = 48 ± 5 min) despite having the lowest LD50 value 
(Broad et al., 1979). However, it has been observed that the rank order of venom lethality, 
as determined from LD50 values, often differs to the rank order of t90 values (Kuruppu et 
al., 2008). The LD50 no doubt reflects contributions of other coagulopathic toxins, 
myotoxins, or neurotoxins with slow on-rates (ie SPANs) to overall toxicity, whereas the t90 
is influenced by neurotoxins with more rapid association kinetics such as postsynaptic α-
neurotoxins. One explanation as to why A. superbus venom has a t90 value that is 
significantly prolonged compared to A. ramsayi and A. labialis venoms appears to be 
because A. superbus venom contains far fewer rapidly-acting short- and long-chain α-
neurotoxins in comparison to the other two Austrelaps venoms (Figs. 4 and 7). 
Previously, venom fractions from A. superbus venom have been shown to cause 
myoglobinuria in mice suggestive of a myolytic action (Mebs and Samejima, 1980). 
Furthermore A. superbus venom has been shown to produce inhibition of twitches evoked 
by direct muscle stimulation and a slowly developing contractile response (Hodgson et al., 
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2003) although, like the present study, responses to KCl were unaffected. In contrast, the 
present study failed to show any clear evidence of myotoxicity, especially a lack of a slowly 
developing increase in baseline muscle tension, from either whole venom or high 
molecular mass fractions from all three Austrelaps venoms. This agrees with clinical 
reports that, unlike Notechis envenoming, major myolysis is not a common symptom in 
copperhead envenoming (White, 1998). However, myolysis should not be discounted as 
myotoxic effects may not be observed as rapidly as postsynaptic neurotoxic effects 
(Wickramaratna et al., 2003). 
Monovalent tiger snake antivenom has previously been shown to be effective in 
neutralising the neurotoxicity of A. superbus venom in vitro (Hodgson et al., 2003). 
Hodgson et al. (2003) also demonstrated a partial ca. 25% recovery of nerve-evoked 
twitch contractions 3 hours after addition of TSAV. The present study confirms the 
effectiveness of TSAV in preventing the neurotoxicity of A. superbus venom, however, 
addition of TSAV at 90% neuromuscular blockade failed to reverse the inhibition of twitch 
contractions. Nevertheless, the present study demonstrates for the first time that TSAV is 
effective in preventing the neurotoxicity caused by A. ramsayi and A. labialis venoms. 
Whilst the addition of TSAV at 90% neuromuscular blockade failed to reverse the inhibition 
of twitch contractions in A. labialis venom, there was a slight recovery of twitch 
contractions with A. ramsayi venom over the course of 3 hours. The MALDI-TOF mass 
profiles and size-exclusion chromatograms reveal that sPLA2 enzymes are more abundant 
in A. superbus and A. labialis venoms than A. ramsayi venom, which is dominated by 
postsynaptic α-neurotoxins. Neurotoxicity associated with several postsynaptic α-
neurotoxins is generally accepted to be ‘reversible’ or ‘pseudo-irreversible’ whereas the 
neurotoxicity associated with many sPLA2 neurotoxins, particularly SPAN complexes, is 
irreversible. This may be due to PLA2-mediated damage to the nerve terminal that 
facilitates SPAN entry (Rigoni et al., 2008), resulting in a loss of accessibility of antibodies 
for the SPAN complex following internalisation of the toxin into the nerve terminal. 
Interestingly, the size-exclusion chromatogram of A. ramsayi venom shows that the 
second major fraction has a delayed retention time (17.4–21.3 min) in comparison to A. 
superbus and A. labialis venoms (14.5–21.6 and 14.7–21.6 min, respectively). The 
estimated mass range of this fraction, from interpolation using the standard curve, 
suggests the presence of only α-neurotoxins with masses between <6.5–12.8 kDa with a 
peak at 7.7 kDa. This indicates why the neurotoxicity caused by A. ramsayi venom is more 
readily reversible with TSAV than with A. superbus and A. labialis venoms.  
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The high molecular mass fraction in all three venoms caused a time-dependent inhibition 
of nerve-evoked twitch contractions without inhibiting contractile responses to exogenous 
nicotinic receptor agonists. Given that the activity of this fraction is prejunctional and falls 
within a molecular mass range that is consistent with that of multimeric SPAN complexes 
previously isolated (Table 1), we therefore propose that these fractions contain multimeric 
SPAN complexes. In support, we previously surmised that a number of Acanthophis 
venoms contain multimeric SPAN complexes based on a similar approach to that used in 
the present study (Blacklow et al., 2010b). This approach has subsequently been validated 
following the characterisation of the heterotrimeric SPAN complexes from these 
Acanthophis venoms (Blacklow et al., 2010a; Chaisakul et al., 2010). At this point it is 
difficult to determine the subunit composition of the SPAN complexes given the broad 
mass range of fraction ƒ1 (42 to > 66 kDa). Elapid venoms are known to contain high 
molecular mass proteins, in addition to multimeric SPAN complexes, including C-type 
lectins (Lin et al., 2007), acetylcholinesterases (Frobert et al., 1997) and L-amino acid 
oxidases (Jin et al., 2007). The latter two enzymes have previously been identified in A. 
superbus venom (Tan and Ponnudurai, 1990). Despite this the estimated mass of the 
SPAN complex would be consistent with at least three sPLA2 subunits. The composition of 
the SPAN complex from each Austrelaps venom is likely to be homologous, but not 
identical given that the MALDI-TOF mass profiles indicate little conservation of sPLA2 
proteins between A. superbus, A. ramsayi and A. labialis venoms (Fig. 7). This may 
explain slight differences in potencies of the high molecular mass fractions. 
A reason why PLA2 activity may have been low, or not detected, in the high molecular 
mass fractions could be due to the presence of acetylcholinesterases and L-amino acid 
oxidases in this fraction that may dilute the apparent concentration of the multimeric SPAN 
complexes. Regardless, previous studies indicate there is little correlation between PLA2 
activity and the degree of neurotoxicity. For example, SPANs such as notexin, from 
Notechis scutatus, have substantial neurotoxic activity and low PLA2 activity, whilst others, 
such as Naja nigricollis neutral sPLA2 enzyme, are weakly neurotoxic but have significant 
PLA2 activity (Rosenberg, 1997; Rossetto et al., 2004).  
Although monovalent TSAV was unable to reverse the prejunctional neurotoxic effects of 
the high molecular mass fractions in all three venoms once toxicity was well established, 
TSAV was found to be effective in neutralising this toxicity in A. superbus and A. labialis 
venoms. Unfortunately, due to limited material, this experiment was unable to be 
performed with the high molecular mass fraction from A. ramsayi.  
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In conclusion, the present study has identified the presence of potent and irreversible 
multimeric SPAN complexes in the venoms of all three species of Australian copperheads 
that represents a significant component (% w/w) of the whole venom. Therefore, clinicians 
need to be aware of the presence of such toxins, as early antivenom treatment is critical 
upon envenomation. The current study also provides the first data to validate the current 
clinical recommendations for the use of TSAV in the treatment of envenomation by all 




Mass spectrometric results were obtained at the Bioanalytical Mass Spectrometry Facility 
at the University of New South Wales using infrastructure provided by the NSW 
Government co-investment in the National Collaborative Research Infrastructure Scheme. 
Subsidised access to this facility is gratefully acknowledged. 
 
References 
Aquilina, J.A., 2009. The major toxin from the Australian Common Brown Snake is a 
hexamer with unusual gas-phase dissociation properties. Proteins 75, 478-485. 
Birrell, G.W., Earl, S.T., Wallis, T.P., Masci, P.P., de Jersey, J., Gorman, J.J., Lavin, M.F., 
2007. The diversity of bioactive proteins in Australian snake venoms. Mol Cell 
Proteomics 6, 973-986. 
Blacklow, B., Escoubas, P., Nicholson, G.M., 2010a. Characterisation of the heterotrimeric 
presynaptic phospholipase A2 neurotoxin complex from the venom of the common 
death adder (Acanthophis antarcticus). Biochem Pharmacol 80, 277-287. 
Blacklow, B., Konstantakopoulos, N., Hodgson, W.C., Nicholson, G.M., 2010b. Presence 
of presynaptic neurotoxin complexes in the venoms of Australo-Papuan death adders 
(Acanthophis spp.). Toxicon 55, 1171-1180. 
Broad, A.J., Sutherland, S.K., Coulter, A.R., 1979. The lethality in mice of dangerous 
Australian and other snake venom. Toxicon 17, 661-664. 
Chaisakul, J., Konstantakopoulos, N., Smith, A.I., Hodgson, W.C., 2010. Isolation and 
characterisation of P-EPTX-Ap1a and P-EPTX-Ar1a: pre-synaptic neurotoxins from the 
venom of the northern (Acanthophis praelongus) and Irian Jayan (Acanthophis rugosus) 
death adders. Biochem Pharmacol 80, 895-902. 
F. Marcon and G. M. Nicholson Neurotoxicity of Australian copperhead snake venoms 
 
 18 
Chetty, N., Du, A., Hodgson, W.C., Winkel, K.D., Fry, B.G., 2004. The in vitro 
neuromuscular activity of Indo-Pacific sea-snake venoms: efficacy of two commercially 
available antivenoms. Toxicon 44, 193-200. 
Chippaux, J.P., Williams, V., White, J., 1991. Snake venom variability: methods of study, 
results and interpretation. Toxicon 29, 1279-1303. 
Chu, C.C., Li, S.H., Chen, Y.H., 1995. Resolution of isotoxins in the β-bungarotoxin family. 
J Chromatogr A 694, 492-497. 
Currie, B.J., 2006. Treatment of snakebite in Australia: the current evidence base and 
questions requiring collaborative multicentre prospective studies. Toxicon 48, 941-956. 
Doley, R., Tram, N.N., Reza, M.A., Kini, R.M., 2008. Unusual accelerated rate of deletions 
and insertions in toxin genes in the venom glands of the pygmy copperhead (Austrelaps 
labialis) from Kangaroo island. BMC Evol Biol 8, 70. 
Fohlman, J., Eaker, D., Karlsson, E., Thesleff, S., 1976. Taipoxin, an extremely potent 
presynaptic neurotoxin from the venom of the Australian snake taipan (Oxyuranus s. 
scutellatus). Isolation, characterization, quaternary structure and pharmacological 
properties. Eur. J. Biochem. 68, 457-469. 
Frobert, Y., Creminon, C., Cousin, X., Remy, M.H., Chatel, J.M., Bon, S., Bon, C., Grassi, 
J., 1997. Acetylcholinesterases from Elapidae snake venoms: biochemical, 
immunological and enzymatic characterization. Biochim Biophys Acta 1339, 253-267. 
Ginsborg, B.L., Warriner, J., 1960. The isolated chick biventer cervicis nerve-muscle 
preparation. Brit. J. Pharmacol. Chemother. 15, 410-411. 
Harris, J.B., Grubb, B.D., Maltin, C.A., Dixon, R., 2000. The neurotoxicity of the venom 
phospholipases A2, notexin and taipoxin. Exp Neurol 161, 517-526. 
Harris, J.B., Karlsson, E., Thesleff, S., 1973. Effects of an isolated toxin from Australian 
Tiger snake (Notechis scutatus scutatus) venom at the mammalian neuromuscular 
junction. Brit. J. Pharmacol. 47, 141-146. 
Harvey, A.L., Barfaraz, A., Thomson, E., Faiz, A., Preston, S., Harris, J.B., 1994. 
Screening of snake venoms for neurotoxic and myotoxic effects using simple in vitro 
preparations from rodents and chicks. Toxicon 32, 257-265. 
Hodgson, W.C., Dal Belo, C.A., Rowan, E.G., 2007. The neuromuscular activity of 
paradoxin: a presynaptic neurotoxin from the venom of the inland taipan (Oxyuranus 
microlepidotus). Neuropharmacology 52, 1229-1236. 
Hodgson, W.C., Eriksson, C.O., Alewood, P., Fry, B.G., 2003. Comparison of the in vitro 
neuromuscular activity of venom from three Australian snakes (Hoplocephalus 
F. Marcon and G. M. Nicholson Neurotoxicity of Australian copperhead snake venoms 
 
 19 
stephensi, Austrelaps superbus and Notechis scutatus): efficacy of tiger snake 
antivenom. Clin Exp Pharmacol Physiol 30, 127-132. 
Jin, Y., Lee, W.H., Zeng, L., Zhang, Y., 2007. Molecular characterization of L-amino acid 
oxidase from king cobra venom. Toxicon 50, 479-489. 
Kini, R.M., 1997. Phospholipase A2–a complex multifunctional protein puzzle. In: Kini, R.M. 
(Ed.) Venom Phospholipase A2 Enzymes: Structure, Function and Mechanism. John 
Wiley & Sons Ltd., Chichester, pp. 1-28. 
Kuruppu, S., Reeve, S., Banerjee, Y., Kini, R.M., Smith, A.I., Hodgson, W.C., 2005a. 
Isolation and pharmacological characterization of cannitoxin, a presynaptic neurotoxin 
from the venom of the Papuan Taipan (Oxyuranus scutellatus canni). J. Pharmacol. 
Exp. Ther. 315, 1196-1202. 
Kuruppu, S., Reeve, S., Smith, A.I., Hodgson, W.C., 2005b. Isolation and pharmacological 
characterisation of papuantoxin-1, a postsynaptic neurotoxin from the venom of the 
Papuan black snake (Pseudechis papuanus). Biochem. Pharmacol 70, 794-800. 
Kuruppu, S., Smith, A.I., Isbister, G.K., Hodgson, W.C., 2008. Neurotoxins from Australo-
Papuan elapids: a biochemical and pharmacological perspective. Crit Rev Toxicol 38, 
73-86. 
Lin, L.P., Lin, Q., Wang, Y.Q., 2007. Cloning, expression and characterization of two C-
type lectins from the venom gland of Bungarus multicinctus. Toxicon 50, 411-419. 
Lumsden, N.G., Fry, B.G., Ventura, S., Kini, R.M., Hodgson, W.C., 2005. Pharmacological 
characterisation of a neurotoxin from the venom of Boiga dendrophila (mangrove 
catsnake). Toxicon 45, 329-334. 
Mebs, D., Samejima, Y., 1980. Purification, from Australian elapid venoms, and properties 
of phospholipases A which cause myoglobinuria in mice. Toxicon 18, 443-454. 
O'Leary, M.A., Isbister, G.K., 2009. Commercial monovalent antivenoms in Australia are 
polyvalent. Toxicon 54, 192-195. 
Ramasamy, S., Isbister, G.K., Hodgson, W.C., 2004. The efficacy of two antivenoms 
against the in vitro myotoxic effects of black snake (Pseudechis) venoms in the chick 
biventer cervicis nerve-muscle preparation. Toxicon 44, 837-845. 
Rawlinson, P.A., 1991. Taxonomy and distribution of the Australian tiger snakes (Notechis) 
and copperheads (Austrelaps) (Serpentes, Elapidae). Proc. Royal Soc. Victoria 103, 
125-135. 
Rigoni, M., Paoli, M., Milanesi, E., Caccin, P., Rasola, A., Bernardi, P., Montecucco, C., 
2008. Snake phospholipase A2 neurotoxins enter neurons, bind specifically to 
F. Marcon and G. M. Nicholson Neurotoxicity of Australian copperhead snake venoms 
 
 20 
mitochondria, and open their transition pores. The Journal of biological chemistry 283, 
34013-34020. 
Rosenberg, P., 1997. Lethal potency of snake venom phospholipase A2 enzymes. In: Kini, 
R.M. (Ed.) Venom Phospholipase A2 Enzymes: Structure, Function and Mechanism. 
John Wiley & Sons Ltd., Chichester, pp. 129-154. 
Rossetto, O., Rigoni, M., Montecucco, C., 2004. Different mechanism of blockade of 
neuroexocytosis by presynaptic neurotoxins. Toxicology Letters 149, 91-101. 
Singh, S., Armugam, A., Kini, R.M., Jeyaseelan, K., 2000. Phospholipase A2 with platelet 
aggregation inhibitor activity from Austrelaps superbus venom: protein purification and 
cDNA cloning. Arch. Biochem. Biophys. 375, 289-303. 
Su, M.J., Coulter, A.R., Sutherland, S.K., Chang, C.C., 1983. The presynaptic 
neuromuscular blocking effect and phospholipase A2 activity of textilotoxin, a potent 
toxin isolated from the venom of the Australian brown snake, Pseudonaja textilis. 
Toxicon 21, 143-151. 
Subburaju, S., Kini, R.M., 1997. Isolation and purification of superbins I and II from 
Austrelaps superbus (copperhead) snake venom and their anticoagulant and 
antiplatelet effects. Toxicon 35, 1239-1250. 
Sutherland, S.K., Tibballs, J., 2001. Genus Austrelaps, death adders.  Australian Animal 
Toxins: The Creatures, Their Toxins and Care of the Poisoned Patient. Oxford 
University Press, Melbourne, pp. 130-138. 
Tan, N., Ponnudurai, G., 1990. A comparative study of the biological properties of 
australian elapid venoms. Comp. Biochem. Physiol. 97C, 99-106. 
White, J., 1998. Envenoming and antivenom use in Australia. Toxicon 36, 1483-1492. 
White, J., 2001. CSL Antivenom Handbook. CSL Ltd., Melbourne. 
Wickramaratna, J.C., Fry, B.G., Aguilar, M.I., Kini, R.M., Hodgson, W.C., 2003. Isolation 
and pharmacological characterization of a phospholipase A2 myotoxin from the venom 
of the Irian Jayan death adder (Acanthophis rugosus). Brit J Pharmacol 138, 333-342. 
Yuan, Y., Jackson, S.P., Mitchell, C.A., Salem, H.H., 1993. Purification and 
characterisation of a snake venom phospholipase A2: a potent inhibitor of platelet 
aggregation. Thrombosis Res. 70, 471-481. 
 
  
F. Marcon and G. M. Nicholson Neurotoxicity of Australian copperhead snake venoms 
 
 21 
Table 1. Characteristics of high molecular mass neurotoxic fractions from Austrelaps 
venoms 
Venom Fraction Elution time 
(min) 
Approx. molecular 
mass range (kDa) 
Yield of fraction 
(%w/w) 
A. superbus ƒ1 10.1 – 13.4 53 to > 66 4.9 
A. ramsayi ƒ1 12.0 – 14.1 41 to > 66 14.4 
A. labialis ƒ1 10.2 – 13.6 49 to > 66 7.2 
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Table 2. Rank order of neurotoxicity of Australo-Papuan terrestrial elapid snake venoms in 
the CBCNM preparation (as determined by t90 values) 
Common Name Scientific name t90 at 10 µg/ml (min) Reference(s) 
Common death adder (NSW) Acanthophis antarcticus  10 ± 1, 14 ± 1 




Curl snake Suta suta 13 ± 1 (Kuruppu et al., 2007) 
Black head death adder Acanthophis wellsi 13 ± 2 (Fry et al., 2001) 








*Highlands copperhead Austrelaps ramsayi 20 ± 1 This study 
Yellow-banded snake Hoplocephalus stephensi 20 ± 2 (Hodgson et al., 2003) 
Tiger snake Notechis scutatus 22 ± 2 (Hodgson et al., 2003) 
Yellow-bellied black snake Pseudechis butleri 22 ± 3 (Ramasamy et al., 2005) 
*Pygmy copperhead Austrelaps labialis 24 ± 1 This study 
Spotted curl snake Suta punctata 25 ± 2 (Kuruppu et al., 2007) 
Red-bellied black snake Pseudechis porphyriacus 25 ± 2 (Ramasamy et al., 2005) 
*Lowlands copperhead Austrelaps superbus 26 ± 3, *48 ± 5 
(Hodgson et al., 
2003), This 
study 
Inland taipan Oxyuranus microlepidotus 27 ± 3 (Crachi et al., 1999a)  
Pygmy mulga snake Pseudechis pailsii 28 ± 1 (Ramasamy et al., 2005) 
Blue-bellied black snake Pseudechis guttatus 30 ± 1 (Ramasamy et al., 2005) 
Papuan black snake Pseudechis papuanus 40 ± 5 (Ramasamy et al., 2005) 
Coastal taipan Oxyuranus scutellatus 42 ± 3 (Crachi et al., 1999a) 
Papuan taipan Oxyuranus scutellatus canni 44 ± 5, 48 ± 5 
(Crachi et al., 
1999a)(Crachi 
et al., 1999b) 
Collett’s snake Pseudechis colletti 56 ± 5 (Ramasamy et al., 2005) 
Brown-headed snake Glyphodon tristis 100 ± 8 (Kuruppu et al., 2005a) 
Mulga or King brown snake Pseudechis australis > 60 (Ramasamy et al., 2005) 
* This study 
  





Fig. 1. Distribution of the three Australian copperhead species. Venom was sourced from 
specimens captured at Kangaroo Island, South Australia (A. labialis), Mount Gambier, 
South Australia (A. superbus) and Davies Plain, Victoria (A. ramsayi). Modified from 
Rawlinson, 1991 (Rawlinson, 1991). 




Fig. 2. Inhibition of indirectly-stimulated twitch contractions by whole Austrelaps venoms in 
the isolated CBCNM preparation. (A-B) Representative twitch tension traces showing the 
action of A. ramsayi venom on neuromuscular transmission and effects of 5 U/ml TSAV to 
prevent and partially reverse neurotoxicity. (Aa) Rapid inhibition of twitch tension following 
application of 10 µg/ml A. ramsayi venom and (Ab) partial reversal of twitch contractions 
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80 min (left panel) and 160 min (right panel) after application of TSAV applied at 90% 
neuromuscular blockade [grey arrowhead labelled TSAV (t90) in panel Aa]. (B) Prevention 
of A. ramsayi venom neurotoxicity by a 10 min preincubation with TSAV (Ba), and 150 min 
after venom application (Bb). (C-E) Timecourse of inhibition of twitch contractions by whole 
venoms (closed circles) showing effects of 10 µg/ml A. superbus (C, n = 6), A. ramsayi (D, 
n = 3) and A. labialis (E, n = 5) in comparison to time-matched controls (open triangles, n = 
4). Partial recovery of twitches after the addition of TSAV at 90% neuromuscular blockade 
was only observed with A. ramsayi venom (open circles). Preincubation of TSAV 10 min 
prior to application of venom successfully prevented onset of neurotoxicity (grey circles, n 
= 3). Note the split x-axis. Data represent the mean ± SEM. ****p < 0.0001 vs. time-
matched control. (F) Scatter dot plot of t90 values for each venom showing mean (wide 
horizontal line), SEM (narrow horizontal lines) and individual t90 values (circles). NS, not 
significant. 
  




Fig. 3. Effect of Austrelaps venoms on slow fibre contractile responses to exogenous 
agonists in the isolated CBCNM preparation. (A) Typical effect of 10 µg/ml A. labialis 
venom on contracture responses to nicotinic agonists and KCl prior to (Aa), and following 
(Ab), 30 min incubation with venom. Panel Ac shows the responses to exogenous agonists 
following a 180 min incubation of 5 U/ml TSAV added at 90% neuromuscular blockade 
(t90). Markers beneath each trace indicate the bath application of either 1 µM ACh, 20 µM 
CCh, or 40 mM KCl (black arrowheads) or washout with Krebs-Henseleit solution (grey 
arrowheads). (B-D) Data shows the percentage of control contracture responses to ACh 
(B), CCh (C) and KCl (D) after complete inhibition of twitch contractions by 10 µg/ml whole 
venom (closed bars) for A. superbus (n = 10), A. ramsayi (n = 3) and A. labialis (n = 5). 
Agonist responses recorded in the presence of 5 U/ml TSAV applied at t90 (open bars) 
were recorded at 180 min in the presence of 10 µg/ml venom from A. superbus (n = 4), A. 
ramsayi (n = 3) and A. labialis (n = 4). Agonist responses recorded in the presence of 5 
U/ml TSAV preincubated 10 min prior to addition of 10 µg/ml of venom from A. superbus (n 
= 3), A. ramsayi (n = 3) and A. labialis (n = 3) (grey bars) were recorded at 60 min. Striped 
column represents time-matched control data recorded after 3-5 hours (n = 11). Note the 
increase in responses with ACh and CCh, and decrease in responses to KCl, from 
contractures recorded at time zero (dashed line). Data represent the mean ± SEM. ***p < 
0.001, ****p < 0.0001, significantly different from time-matched control response, two-way 
ANOVA. 
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Fig. 4. Size-exclusion FPLC separation of Austrelaps venoms under non-reducing 
conditions. (A) Log molecular weight vs. retention ratio (Ve / Vo) standard curve for the 
calibration of the Superdex G-75 column using a series of molecular weight standards. 
Calibrants were eluted with ammonium acetate (0.1 M NH4Ac, pH 6.8) at a flow rate of 
0.75 ml/min (open squares). Representative size-exclusion FPLC chromatograms from A. 
superbus (B), A. ramsayi (C) and A. labialis (C) under non-reducing conditions with an 
isocratic flow of 0.1 M NH4Ac pH 6.8 (grey dotted line) at 0.75 ml/min. Dark grey shaded 
fractions labelled ‘ƒ1’ representing high molecular mass components (Mr 41 kDa to > 66 
kDa) were collected for subsequent analysis. The two areas of the elution profile 
highlighted in light grey, from 17–19.2 min, indicate the mass range of sPLA2 proteins 
(12,700–14,800 kDa; left hand bar) and postsynaptic α-neurotoxins (6,700–8,850 kDa; 
right hand bar). Elution of proteins was monitored at 280 nm.  
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Fig. 5. Inhibition of indirectly-stimulated twitch contractions by the high molecular mass 
fraction (ƒ1) of Austrelaps venoms in the CBCNM preparation. Timecourse of inhibition of 
twitch contractions by 10 µg/ml ƒ1 (closed circles) from (A) A. superbus (n = 6) (B), A. 
ramsayi (n = 3) and (C) A. labialis (n = 3) in comparison to time-match controls (n = 4; 
open triangles). No recovery of twitch contractions was observed after the addition of 5 
U/ml TSAV following complete neuromuscular blockade (n = 3; open circles). Note the split 
x-axis. A 10 min preincubation of 5 U/ml TSAV prior to application of ƒ1 from A. superbus 
and A. labialis was able to prevent the onset of neurotoxicity (n = 3; grey circles). The 
efficacy of TSAV in preventing the onset of neurotoxicity with ƒ1 from A. ramsayi was not 
determined. Data represent the mean ± SEM. (D) Scatter dot plot of t90 values for ƒ1 from 
each venom showing mean (wide horizontal line), SEM (narrow horizontal lines) and 
individual t90 values (squares).  




Fig. 6. Effect of the high molecular mass fraction (ƒ1) of Austrelaps venoms on slow fibre 
contractile responses to exogenous agonists in the isolated CBCNM preparation. (A-C) 
Data shows the percentage of control contracture responses to ACh (A), CCh (B) and KCl 
(C) after complete inhibition of twitch contractions by 10 µg/ml ƒ1 (closed bars) from A. 
superbus (n = 6), A. ramsayi (n = 3) and A. labialis (n = 3). Agonist responses recorded in 
the presence of 5 U/ml antivenom applied at t90 (open bars) following application of 10 
µg/ml ƒ1 from A. superbus (n = 3), A. ramsayi (n = 3) and A. labialis (n = 3) were recorded 
at 180 min. Agonist responses recorded in the presence of 5 U/ml antivenom preincubated 
10 min prior to addition of 10 µg/ml ƒ1 from A. superbus (n = 3) and A. labialis (n = 3) from 
were recorded at 60 min (grey bars). ND, not determined. Striped column represents time-
matched control data recorded after 3-5 hours (n = 11). Note the increase in responses 
with ACh and CCh, and decrease in responses to KCl, from contractures recorded at time 
zero (dashed line). Data represent the mean ± SEM. **p < 0.01, significantly different from 
time-matched control, two-way ANOVA.  




Fig. 7. PLA2 activity of whole Austrelaps venoms and their high molecular mass fraction 
(ƒ1). Left hand columns show PLA2 activity of whole venom from A. superbus (open bar, n 
= 3), A. ramsayi (grey bar, n = 4) and A. labialis (closed bar, n = 3) as determined using 
the sPLA2 assay kit. Bee (Apis mellifera) venom (left-hand stippled bar, n = 11) was used 
as a positive control. Right hand columns show PLA2 activity of the high molecular mass 
fraction ƒ1 from A. superbus (open bar, n = 4), A. ramsayi (grey bar, n = 2) and A. labialis 
(closed bar, n = 4). Note that PLA2 activity was not detected in A. ramsayi venom or ƒ1 
fraction. 




Fig. 8. MALDI-TOF mass spectra of Austrelaps venoms. Spectra are focused on masses 
(m/z) consistent with the presence of short-chain α-neurotoxins (‘Short’, light grey), long-
chain α-neurotoxins (‘Long’, dark grey) and monomeric sPLA2 proteins (‘PLA2’, black). 
Major peaks are labelled, while a complete mass list is shown to the right of each panel. 
Masses common to at least two venoms are highlighted. Note the split x-axis. 
